Invesco Exchange-Traded Fund Trust II has disclosed its latest financial figures, revealing a total asset value of approximately $280 million as of August 31, 2026. This update is significant as it reflects the trust's ongoing performance and investment strategies within the investment sector.
The filing, submitted on October 30, 2026, shows that Invesco Trust's net assets stand at about $250 million, indicating a solid position in the competitive landscape of exchange-traded funds (ETFs). The report highlights the trust's financial health and its ability to manage assets effectively, which is crucial in the current investment climate.
Background
Invesco Exchange-Traded Fund Trust II is a prominent player in the investment sector, known for its management of exchange-traded funds. The trust operates under the Central Index Key (CIK) number 0001378872 and has a filing history that includes various forms related to its financial disclosures. The trust's business address is located at 3500 Lacey Road, Suite 700, Downers Grove, IL 60515.
What the Filing Says
The latest filing, identified by accession number 0001378872-26-001859, provides a comprehensive overview of the trust's financial standing. It states, "Total Assets: $280,097,423.84" and "Net Assets: $250,559,789.78," showcasing the trust's robust asset management capabilities.
Impact
This financial update may impact various stakeholders, including investors, analysts, and competitors in the ETF market. The reported figures could influence investor confidence in Invesco Trust's management and investment strategies, while also prompting competitors to assess their own performance in light of these results.
What's Next
The filing does not specify what happens next for Invesco Exchange-Traded Fund Trust II, leaving stakeholders to anticipate further updates or strategic moves from the trust in the coming months.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






